{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:37:03Z","timestamp":1792089423864,"version":"4.4.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by deletion or mutation of the <jats:italic>SMN1<\/jats:italic> gene. It is characterized by a progressive loss of motor neurons resulting in muscle weakness. The disease affects 1 in 11,000 live births and before the era of treatment SMA was a leading genetic cause of mortality in infants. Recently, disease modifying therapies have been introduced in clinical practice. They include intrathecal and oral antisense oligonucleotides binding to pre-mRNA of <jats:italic>SMN2<\/jats:italic> gene and increasing the translation of fully functional SMN protein as well as <jats:italic>SMN1<\/jats:italic> gene replacement therapy. Onasemnogene abeparvovec uses the adeno-associated virus 9 (AAV9) vector to deliver the <jats:italic>SMN1<\/jats:italic> gene. Phase 1 and phase 3 clinical trials showed that a single administration of onasemnogene abeparvovec resulted in improvement of motor functions in the majority of infants with SMA. Currently, phase 3 trials in SMA1 and SMA2 patients, as well as presymptomatic infants diagnosed with SMA, are ongoing. The drug was approved for medical use in the US in 2019, and in Japan and the European Union in 2020. Thus, first real-world data on efficacy and safety of onasemnogene abeparvovec in SMA patients are available.<\/jats:p>","DOI":"10.3389\/fneur.2021.726468","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:04:53Z","timestamp":1634148293000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy"],"prefix":"10.3389","volume":"12","author":[{"given":"Katarzyna","family":"Kotulska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Fattal-Valevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Haberlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years","volume":"16","author":"Vill","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.nmd.2020.10.005","article-title":"Impact of a national population-based carrier-screening program on spinal muscular atrophy births","volume":"30","author":"Aharoni","year":"2020","journal-title":"Neuromuscul Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JND-190465","article-title":"Feeding and swallowing problems in infants with spinal muscular atrophy type 1: an observational study","volume":"7","author":"van der Heul","year":"2020","journal-title":"J Neuromuscul Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.nmd.2020.12.007","article-title":"Feeding difficulties in children and adolescents with spinal muscular atrophy type 2","volume":"31","author":"Wadman","year":"2021","journal-title":"Neuromuscul Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.sleep.2016.11.012","article-title":"Sleep disorders in spinal muscular atrophy","volume":"30","author":"Pera","year":"2017","journal-title":"Sleep Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/s0960-8966(01)00274-7","article-title":"Intelligence and cognitive function in children and adolescents with spinal muscular atrophy","volume":"12","author":"von Gontard","year":"2002","journal-title":"Neuromuscul Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13023-020-01661-9","article-title":"Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA)","volume":"16","author":"Mix","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B10","first-page":"423","article-title":"International SMA consortium meeting","volume-title":"Neuromuscul Disord.","author":"Munsat","year":"1992"},{"key":"B11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nmd.2017.09.015","article-title":"Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy","volume":"28","author":"De Sanctis","year":"2018","journal-title":"Neuromuscul Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","article-title":"Longitudinal natural history of type I spinal muscular atrophy: a critical review","volume":"15","author":"Mercuri","year":"2020","journal-title":"Orphanet J Rare Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ana.25900","article-title":"Clinical variability in spinal muscular atrophy type III","volume":"88","author":"Coratti","year":"2020","journal-title":"Ann Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-021-01771-y","article-title":"Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy","volume":"16","author":"Lusakowska","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ene.14587","article-title":"Clinical and radiological profile of patients with spinal muscular atrophy type 4","volume":"28","author":"Souza","year":"2021","journal-title":"Eur J Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/ejpn.1999.0181","article-title":"Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype","volume":"3","author":"Dubowitz","year":"1999","journal-title":"Eur J Paediatr Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","article-title":"Spinal muscular atrophy - insights and challenges in the treatment era","volume":"16","author":"Mercuri","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell."},{"key":"B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/s0092-8674(00)80367-0","article-title":"The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins","volume":"90","author":"Liu","year":"1997","journal-title":"Cell."},{"key":"B23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat Rev Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.nmd.2007.02.006","article-title":"The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study","volume":"17","author":"Tiziano","year":"2007","journal-title":"Neuromuscul Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci Transl Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J Neuromuscul Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/dmcn.14412","article-title":"Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen","volume":"62","author":"Aragon-Gawinska","year":"2020","journal-title":"Dev Med Child Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5603\/PJNNS.a2021.0020","article-title":"Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland","volume":"55","author":"Modrzejewska","year":"2021","journal-title":"Neurol Neurochir Pol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3233\/JND-210644","article-title":"Effect of discontinuation of nusinersen treatment in long-standing SMA3","volume":"8","author":"Hiebeler","year":"2021","journal-title":"J Neuromuscul Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs."},{"key":"B40","first-page":"2","article-title":"FIREFISH part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA)","volume-title":"Poster Presented at: 25th International Annual Congress of the World Muscle Society; September 28\u2013 October","author":"Baranello","year":"2020"},{"key":"B41","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/hmg\/ddq514","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","volume":"20","author":"Dominguez","year":"2011","journal-title":"Hum Mol Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1093\/hmg\/ddq300","article-title":"Early heart failure in the SMND7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery","volume":"19","author":"Bevan","year":"2010","journal-title":"Hum Mol Genet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose\u2013response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit","volume":"24","author":"Van Alstyne","year":"2021","journal-title":"Nat Neurosci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12033-015-9899-5","article-title":"Large-scale production of adeno-associated viral vector serotype-9 carrying the human survival motor neuron gene","volume":"58","author":"Rashnonejad","year":"2016","journal-title":"Mol Biotechnol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddab220.","article-title":"SMN protein is required throughout life to prevent spinal muscular atrophy disease progression","author":"Zhao","year":"2021","journal-title":"Hum Mol Genet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 Receiving single-dose gene replacement therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMc1715769","article-title":"Therapy for spinal muscular atrophy","volume":"378","author":"Mendell","year":"2018","journal-title":"N Engl J Med."},{"key":"B57","article-title":"Long-Term Follow-up (LTFU) of onasemnogene abeparvovec gene therapy in Spinal Muscular Atrophy","author":"Mendell","year":"2021","journal-title":"2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference"},{"key":"B58","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag."},{"key":"B60","article-title":"Onasemnogene abeparvovec gene therapy in presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT study update in children with three copies of SMN2","author":"Strauss","year":"2021","journal-title":"2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference"},{"key":"B61","article-title":"Onasemnogene abeparvovec gene therapy in presymptomatic Spinal Muscular Atrophy (SMA)","author":"Strauss","year":"2021","journal-title":"SPR1NT Study Update in Children with Two Copies of SMN2. 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference"},{"key":"B62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-190451","article-title":"RESTORE: a prospective multinational registry of patients with genetically confirmed spinal muscular atrophy - rationale and study design","volume":"7","author":"Finkel","year":"2020","journal-title":"J Neuromuscul Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J Pediatr."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics."},{"key":"B66","unstructured":"Thrombotic Microangiopathy (TMA): a potential adverse reaction post Zolgensma (onasemnogene abeparvovec-xioi) therapy for Spinal Muscular Atrophy (SMA) (5483)5483\n            PrabhuN\n            SaylamE\n            LouisC\n            MossM\n            MillnerR\n            DouglassD\n          Neurology.942020"},{"key":"B67","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J Pediatr."},{"key":"B68","doi-asserted-by":"publisher","first-page":"105488","DOI":"10.1016\/j.nbd.2021.105488","article-title":"Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic \u03947SMA mice","volume":"159","author":"Kray","year":"2021","journal-title":"Neurobiol Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination molecular therapies for type 1 spinal muscular atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve."},{"key":"B70","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0883073820928784","article-title":"Clinical course in a patient with spinal muscular atrophy type 0 treated with nusinersen and onasemnogene abeparvovec","volume":"35","author":"Matesanz","year":"2020","journal-title":"J Child Neurol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mus.27375","article-title":"Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1","volume":"64","author":"Oechsel","year":"2021","journal-title":"Muscle Nerve."},{"key":"B72","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur J Paediatr Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.726468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:05:01Z","timestamp":1634148301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.726468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":72,"alternative-id":["10.3389\/fneur.2021.726468"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.726468","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]},"article-number":"726468"}}